Glycosylation, hypogammaglobulinemia, and resistance to viral infections - Wikidata - awgldk - TriplyDB

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

http://www.wikidata.org/entity/Q33789632

about

The National Institutes of Health undiagnosed diseases program CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection.HIV-1 envelope glycan moieties modulate HIV-1 transmission.In vivo therapeutic protection against influenza A (H1N1) oseltamivir-sensitive and resistant viruses by the iminosugar UV-4.Novel primary immunodeficiency candidate genes predicted by the human gene connectome Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections.A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue)Glycans Instructing Immunity: The Emerging Role of Altered Glycosylation in Clinical Immunology.Mitotic Intragenic Recombination: A Mechanism of Survival for Several Congenital Disorders of Glycosylation Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease.Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation Iminosugar antivirals: the therapeutic sweet spot.Immunological aspects of congenital disorders of glycosylation (CDG): a review.The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine.Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2.Neutralization function affected by single amino acid replacement in the HIV-1 antibody targets.Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.Characteristic dysmorphic features in congenital disorders of glycosylation type IIb.p32 regulates ER stress and lipid homeostasis by down-regulating GCS1 expression.Clinical glycomics for the diagnosis of congenital disorders of glycosylation.

P2860

Q26998733-5E43FC8A-D2D0-4BF0-AC85-F6BF9C142D5C Q33826506-BF91BDE4-948D-47DC-A4CA-B8D71CB9F571 Q34595009-C414D94C-2344-470A-AC10-FECEAD929550 Q35191986-C69644A3-A7B5-448B-AFDB-53AB3FA713A3 Q35238656-9198EB11-D907-4400-AC63-BBF70604481E Q35656099-262FF2CA-F610-4435-B4CC-40CA7280B4C2 Q35676012-0B7E4EE3-F3DB-4F54-99FD-982B12FD2CC8 Q35725275-28187A11-E7A2-4F5B-BD10-DFEAD1E4DED0 Q36559149-B837BCE7-CD80-4AC0-893B-ABC39DE996BB Q36665114-5F7E3F71-A3FE-414F-A6A6-02176581DD1D Q37340035-69AA7A60-9338-4A81-8C4C-7AE9A9E9AF3B Q38373599-AA05515C-F90B-479B-AC5D-61C546F29C97 Q38688788-08ABAA60-44C2-4A1A-BCC9-57962323B5CE Q38730551-34C99FB9-C63B-4554-888E-D5F5A01E8CDB Q38890624-66A5CE43-EB66-47D0-9414-5912DB44A068 Q40929545-DB77E2FA-2496-43EB-9FCC-053C9BAD1C8F Q41687420-ECCA88AA-844A-4601-8F18-3F3EF2AD7457 Q41922279-52438F5A-ECA5-425C-AA0A-95E66CD3ADB4 Q47558474-B59EA0BC-8599-4210-8DBD-FD6535E1BF3A Q48126829-34B4EE3D-C2E9-4A5C-B4C2-E431023C6E57 Q49714205-DFA0A521-98E1-4A45-B6CA-80E69EA88E96 Q54959588-E0016927-F73B-4738-BD4E-75161278833E

P2860

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

http://www.wikidata.org/entity/Q33789632

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@ast

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@en

type

label

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@ast

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@en

prefLabel

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@ast

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@en

P1433

Q33789632-3443090B-4FF1-4747-806C-01B41114C485

P1476

Q33789632-2B6D64B6-E6A6-47D2-87FD-610943C0981E

P2093

Q33789632-011E4632-62B0-447C-A466-35E26F21BF81

Q33789632-0313B720-A360-4D14-9C79-0FC1464BA829

Q33789632-04B2CC7F-EC26-40AB-896B-3DC7D128E832

Q33789632-0DDAD631-CD03-421B-B57E-1E47B5409EB1

Q33789632-12ED4735-16CD-4668-B8CB-43916D839496

Q33789632-1FD1DDB4-CC17-4830-8CBD-224E05CF47E9

Q33789632-20A0F648-CC24-4D8F-A183-748C271629E8

Q33789632-289B484F-B8FB-437C-80C7-6122A14FB2C4

Q33789632-30E4F50B-14AA-41D6-9E9C-2B34D311FBEB

Q33789632-3759DBC5-31B3-4537-8529-81A3BEA525A9

P2860

Q33789632-026201FB-A7CC-4133-BD41-1A99FA7AE15C

Q33789632-0B0108A3-013C-4864-AC32-DE8160C8EEF9

Q33789632-0D074C84-B380-4C78-9C31-DF9AEAE0780A

Q33789632-10AEC537-3964-4428-8DDC-F5AC597CAFE6

Q33789632-300DBB2A-B01A-4F61-AE8E-3D406389867D

Q33789632-48FFA5FF-C4CE-4BDA-8659-294F29550A94

Q33789632-539C1E98-C5A4-4C30-B9E7-D019E932CE23

Q33789632-5758A1C9-8212-44CB-9784-6C724154A895

Q33789632-5A6ECB1D-1EE6-4E35-A210-DB2BC4729DC7

Q33789632-88B33A42-7322-4A58-920E-9A5DE4644261

P304

Q33789632-C261B53D-30D9-418D-BA49-097392E275FF

P31

Q33789632-EE225DAF-8C1E-4A92-9EBC-496D1AF04943

P356

Q33789632-936DDA77-E50E-428A-B659-A96BFC5B5419

P407

Q33789632-9007BEC8-0112-4441-9FE9-98BD0827FD0A

P433

Q33789632-F5A57A7D-6433-47FB-B12C-4720B86C9704

P478

Q33789632-C010B9B1-3844-4C46-809A-48446C722671

P50

Q33789632-63790866-5750-4B51-B63D-847690FF8726

Q33789632-9B46A50E-E6CC-42CF-B1B8-A486CC127859

Q33789632-E2268F44-82A0-4372-9333-FD225678AC30

P577

Q33789632-A8CFD90C-8232-4411-9638-02D4D7B4896C

P698

Q33789632-C252A78F-7E74-40DE-8BA3-3E02B3ECE333

P921

Q33789632-96A54C10-82AC-4E95-9B95-991DB22D3E29

P932

Q33789632-6B089830-C704-4A79-AF09-DFECA9A1D11A

P356

P1433

The New England Journal of Medicine

P1476

Glycosylation, hypogammaglobulinemia, and resistance to viral infections

@en

P2093

Aaron Louie

http://www.w3.org/2001/XMLSchema#string

Beatriz E Marciano

http://www.w3.org/2001/XMLSchema#string

Claire Grunes

http://www.w3.org/2001/XMLSchema#string

Cornelius F Boerkoel

http://www.w3.org/2001/XMLSchema#string

Daniel Salahuddin

http://www.w3.org/2001/XMLSchema#string

Daniela Verthelyi

http://www.w3.org/2001/XMLSchema#string

Danielle Murray

http://www.w3.org/2001/XMLSchema#string

David Adams

http://www.w3.org/2001/XMLSchema#string

Debra A Long Priel

http://www.w3.org/2001/XMLSchema#string

Derek C Ireland

http://www.w3.org/2001/XMLSchema#string

P2860

A Dengue Fever Viremia Model in Mice Shows Reduction in Viral Replication and Suppression of the Inflammatory Response after Treatment with Antiviral Drugs

A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency.

A rapid mass spectrometric strategy for the characterization of N- and O-glycan chains in the diagnosis of defects in glycan biosynthesis.

The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.

CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir.

Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity.

Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children.

N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure

P304

1615-1625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1302846

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

Matthew J Memoli

P577

2014-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24716661

http://www.w3.org/2001/XMLSchema#string

P921

P932

4066413

http://www.w3.org/2001/XMLSchema#string